MetaCap

Bambusa Therapeutics Inc. Company Profile

NASDAQ: BBTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

16.00+0.45 (+2.89%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Bambusa Therapeutics at a glance

Bambusa Therapeutics Inc. (NASDAQ: BBTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Bambusa Therapeutics is led by Dr. Shanshan Xu M.B.A., M.D., Ph.D. and employs about 26 people. The company's shares have traded publicly since 2026.

At a market capitalization of $815.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0002044950, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Bambusa Therapeutics do?

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Bambusa Therapeutics Inc.
Ticker
NASDAQ: BBTX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Shanshan Xu M.B.A., M.D., Ph.D.
Employees
26
Headquarters
22 Boston Wharf Road, Boston, MA, United States
Phone
(617) 848-6188
IPO year
2026
Market cap
$815.08M
SEC CIK
0002044950

Companies similar to Bambusa Therapeutics

BBTX peer companies
CompanyPrice% ChgMarket capCompare
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs BBTX
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs BBTX
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs BBTX
IMTXImmatics N.V.5.77-3.03%$878.58Mvs BBTX
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs BBTX
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs BBTX
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs BBTX
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs BBTX

Related